IDEXX Laboratories, Inc.
Every calculator, already run for IDXX
Open the full toolkit →You have the numbers on IDXX. Get the argument.
A written report on which of these readings actually decide the outcome for IDEXX Laboratories, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
14 analysts covering IDXXAnalyst Price Target Disagreement for IDEXX Laboratories, Inc.
Wall Street's bull case implies +56% from the current price; the bear case implies -9%. A 65% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for IDXX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, includ…
IDXX — frequently asked
Is IDXX a buy right now?
Wall Street's consensus rating on IDEXX Laboratories, Inc. is Buy across 14 analysts, with a mean price target of $698.92 (+35% vs. the current $517.63). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is IDXX overvalued?
IDXX trades at 36.4x trailing earnings, against a DCF fair value of $163 per share. The current price implies 23% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is IDXX's next earnings date?
IDEXX Laboratories, Inc. is next scheduled to report earnings around Nov 2, 2026. A full IDXX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for IDEXX Laboratories, Inc.?
Analysts covering IDEXX Laboratories, Inc. (IDXX) range from a bear-case target of $470.00 to a bull-case high of $805.00, with a mean consensus target of $698.92 across 13 analysts. The spread of $335.00 (65% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare IDEXX Laboratories, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For IDEXX Laboratories, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full IDXX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on IDEXX Laboratories, Inc., in minutes. 3 free reports included with every account — no credit card required.